Ranbaxy Laboratories, India's top drug maker by sales, said on Monday it had launched a new skin-care drug in the domestic market under a licencing pact with Japan's Summit Pharmaceuticals International.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, will have exclusive marketing rights for Lulifin in India as part of the agreement with Summit Pharmaceuticals, the Indian drug maker said in a statement.
The company said the new drug would strengthen its position in the dermatology market.
Comments